{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:30:33Z","timestamp":1785306633417,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Kidney stones are a common disorder with increasing global prevalence. Metabolic dysfunction-associated steatotic liver disease (MASLD), a systemic metabolic condition, has been suggested to be linked with kidney stones, but existing evidence is inconsistent. This study aimed to clarify the association between MASLD and kidney stones risk using both cross-sectional and cohort analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1,875 participants from a cross-sectional study and 1,903 from a community-based cohort were analyzed. Logistic regression was used in the cross-sectional study, while incidence rates, Kaplan\u2013Meier curves, log-rank tests, and Cox models estimated risk in the cohort. Subgroup and mediation analyses were performed, with METS-IR, WBC, and eGFR examined as mediators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the cohort study, there were 94 incident kidney stone cases identified during a median follow-up of 34.62 months, with an incidence rate of 17.6 per 1,000 person-years. In the cross-sectional analysis, MASLD was positively associated with kidney stones, with an odds ratio (OR) of 1.466 (95% CI: 1.059\u20132.028) after adjustment for potential confounders. Kaplan\u2013Meier analysis revealed significant differences in cumulative incidence between MASLD and non-MASLD groups (log-rank P &amp;lt; 0.001). Cox regression confirmed MASLD as an independent risk factor for kidney stones (HR = 2.04, 95% CI: 1.29\u20133.23). Subgroup analyses showed consistent associations in metabolically high-risk individuals. Mediation analyses further highlighted METS-IR as a key mediator linking MASLD to kidney stone formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MASLD was independently associated with increased kidney stone risk, particularly in metabolically high-risk individuals. METS-IR mediated this relationship, underscoring the critical role of insulin resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1752891","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:16:28Z","timestamp":1770009388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between metabolic dysfunction-associated steatotic liver disease and kidney stone risk in individuals with metabolic dysfunction: evidence from cross-sectional and cohort analyses"],"prefix":"10.3389","volume":"17","author":[{"given":"Yushuang","family":"Wei","sequence":"first","affiliation":[{"name":"School of Public Health, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boteng","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Public Health, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihua","family":"Lai","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengnan","family":"Mo","sequence":"additional","affiliation":[{"name":"Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Yulin","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/healthcare11030424","article-title":"Epidemiology of kidney stones","volume":"11","author":"Stamatelou","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/bju.16179","article-title":"Prevalence of urolithiasis in China: a systematic review and meta-analysis","volume":"133","author":"Tan","year":"2024","journal-title":"BJU Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2016.11.024","article-title":"The role of the microbiome in kidney stone formation","volume":"36","author":"Mehta","year":"2016","journal-title":"Int J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0332-x","article-title":"Genetics of kidney stone disease","volume":"17","author":"Howles","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0320-7","article-title":"Determining the true burden of kidney stone disease","volume":"16","author":"Thongprayoon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2014.06.03","article-title":"Metabolic syndrome and nephrolithiasis","volume":"3","author":"Ramaswamy","year":"2014","journal-title":"Transl Androl Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: Definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1111\/liv.70017","article-title":"MetALD: new perspectives on an old overlooked disease","volume":"45","author":"Ayares","year":"2025","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.4.455","article-title":"Obesity, weight gain, and the risk of kidney stones","volume":"293","author":"Taylor","year":"2005","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68071-9","article-title":"Kidney stones: pathophysiology and medical management","volume":"367","author":"Moe","year":"2006","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.02.008","article-title":"Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus","volume":"83","author":"Spatola","year":"2018","journal-title":"Metabolism"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027702","article-title":"The association between a non-invasive hepatic fibrosis score and urolithiasis among non-alcoholic fatty liver disease (NAFLD) patients in China: a cross-sectional study","volume":"9","author":"Qin","year":"2019","journal-title":"BMJ Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2016.07.004","article-title":"Association of non-alcoholic fatty liver disease with renal stone disease detected on computed tomography","volume":"3","author":"Nam","year":"2016","journal-title":"Eur J Radiol Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.106824","article-title":"Metabolic dysfunction-associated fatty liver disease as a mediator of urolithiasis risk: evidence from cross-sectional and genetic studies","volume":"22","author":"Miao","year":"2025","journal-title":"Int J Med Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012092","article-title":"Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis","volume":"97","author":"Qin","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0883","article-title":"METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes","volume":"178","author":"Bello-Chavolla","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary","volume":"67","year":"2024","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/end.2020.0486","article-title":"Nonalcoholic fatty liver disease is an independent risk factor for nephrolithiasis in women: findings from NHANES III","volume":"34","author":"Decker","year":"2020","journal-title":"J Endourol"},{"key":"B21","article-title":"Epidemiologic association of nonalcoholic fatty liver disease and urinary calculi: a population-based cross-sectional study in southern China","volume":"12","author":"Wei","year":"2018","journal-title":"Iran J Kidney Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/end.2011.0130","article-title":"Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey","volume":"25","author":"Holoch","year":"2011","journal-title":"J Endourol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1597995","article-title":"Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota","volume":"16","author":"Yang","year":"2025","journal-title":"Front Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001539","article-title":"Bile acid signaling in MASLD: From pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00240-015-0846-5","article-title":"The management of patients with enteric hyperoxaluria","volume":"44","author":"Asplin","year":"2016","journal-title":"Urolithiasis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00790.x","article-title":"Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion","volume":"66","author":"Ferraz","year":"2004","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"115936","DOI":"10.1016\/j.celrep.2025.115936","article-title":"Gut microbiota-bile acid crosstalk contributes to calcium oxalate nephropathy through Hsp90\u03b1-mediated ferroptosis","volume":"44","author":"Liu","year":"2025","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"110570","DOI":"10.1016\/j.cbi.2023.110570","article-title":"Untargeted and targeted metabolomics reveal bile acid profile changes in rats with ethylene glycol-induced calcium oxalate nephrolithiasis","volume":"381","author":"Zhou","year":"2023","journal-title":"Chem Biol Interact"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1444049","article-title":"Association between insulin resistance indices and kidney stones: results from the 2015\u20132018 National Health and Nutrition Examination Survey","volume":"11","author":"Shen","year":"2024","journal-title":"Front Nutr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1554798","article-title":"Association between steatotic liver disease and microvascular complications in individuals with type 2 diabetes: a cohort study in the UK Biobank","volume":"16","author":"Liu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101820","DOI":"10.1016\/j.xcrm.2024.101820","article-title":"Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis","volume":"5","author":"Sabatini","year":"2024","journal-title":"Cell Rep Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.jhepr.2024.101092","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1322288","article-title":"Bile acid receptors and renal regulation of water homeostasis","volume":"14","author":"Guo","year":"2023","journal-title":"Front Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9387","article-title":"Study on the pathogenesis and prevention strategies of kidney stones based on GC-MS combined with metabolic pathway analysis","volume":"36","author":"Xie","year":"2022","journal-title":"Rapid Commun Mass Spectrom"},{"key":"B37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/nu12030779","article-title":"Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian-vegan diets","volume":"12","author":"Ferraro","year":"2020","journal-title":"Nutrients"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1752891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:28:52Z","timestamp":1771925332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1752891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1752891"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1752891","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1752891"}}